Losartan (DB00678): A Comprehensive Monograph on the Archetypal Angiotensin II Receptor Blocker

Executive Summary

Losartan stands as a landmark therapeutic agent in cardiovascular medicine, distinguished as the first orally active, nonpeptide Angiotensin II Receptor Blocker (ARB) to be developed and approved for clinical use.[1] Its introduction fundamentally altered the therapeutic landscape for hypertension and related cardiovascular disorders, offering a novel mechanism of action with a distinct tolerability profile compared to its predecessors. As a small molecule drug identified by DrugBank ID DB00678 and CAS Number 114798-26-4, Losartan represents the progenitor of the "sartan" class of medications.[2]

The core mechanism of Losartan involves its function as a selective and competitive antagonist of the Angiotensin II Type 1 (AT1) receptor.[4] By blocking this receptor, Losartan effectively prevents the potent vasoconstrictive and aldosterone-secreting effects of angiotensin II, the primary effector hormone of the Renin-Angiotensin System (RAS).[6] This blockade results in vasodilation, a reduction in total peripheral resistance, and consequently, a lowering of systemic blood pressure, establishing it as a cornerstone therapy for hypertension.[3]

The United States Food and Drug Administration (FDA) has approved Losartan for several key indications. Its primary use is in the management of hypertension in both adult and pediatric populations (aged 6 years and older).[3] Beyond simple blood pressure control, it is also indicated for the reduction of stroke risk in patients with hypertension and associated left ventricular hypertrophy (LVH), a benefit that clinical evidence suggests may not be applicable to patients of African heritage.[3] Furthermore, Losartan is approved for the treatment of diabetic nephropathy in patients with type 2 diabetes and a history of hypertension, where it serves to delay the progression of renal disease.[3]

A critical aspect of Losartan's pharmacology is its nature as a prodrug. Following oral administration, it undergoes significant first-pass metabolism, with approximately 14% of the dose being converted to a pharmacologically active carboxylic acid metabolite, E-3174.[4] This metabolite is 10 to 40 times more potent than the parent compound and possesses a significantly longer half-life, which is largely responsible for Losartan's sustained 24-hour antihypertensive effect and the convenience of once-daily dosing.[4] A key comparative advantage that propelled Losartan's widespread adoption is its significantly lower incidence of cough compared to Angiotensin-Converting Enzyme (ACE) inhibitors, a common and often treatment-limiting side effect of the older drug class.[3] This favorable tolerability profile, combined with its proven efficacy, has secured Losartan's position on the World Health Organization's List of Essential Medicines and cemented its role as a vital tool in modern pharmacotherapy.[4]

History and Development

The story of Losartan's discovery and development is a compelling narrative of strategic corporate risk, scientific serendipity, rational drug design, and crucial collaboration. It illustrates a paradigm of modern pharmaceutical innovation, where a novel biological concept was translated into a multibillion-dollar, first-in-class therapeutic agent against considerable odds.

2.1 The Scientific Context: Targeting the Renin-Angiotensin System (RAS)

By the 1970s and early 1980s, the scientific community had firmly established the Renin-Angiotensin System (RAS) as a central pathway in the regulation of blood pressure and fluid balance.[2] This understanding spurred intense interest within the pharmaceutical industry to develop drugs that could modulate this system. The initial breakthrough came with the development of Angiotensin-Converting Enzyme (ACE) inhibitors, which block the conversion of angiotensin I to the potent vasoconstrictor angiotensin II. While highly effective, ACE inhibitors were associated with a persistent, dry cough in a significant portion of patients, creating a clear unmet medical need for an alternative approach.[2]

The next logical target was the angiotensin II receptor itself. Early attempts to develop antagonists focused on peptide analogues of angiotensin II. However, this line of research was fraught with challenges and ultimately proved unsuccessful. These peptide-based compounds uniformly lacked oral bioavailability, possessed very short biological half-lives (some lasting only minutes), and in some cases, exhibited undesirable partial agonist activity, limiting their therapeutic potential.[1] The field was in search of a nonpeptide, orally active antagonist, a goal that many in the industry considered exceptionally difficult, if not impossible, to achieve.

2.2 The DuPont Endeavor: A Story of Risk, Serendipity, and Persistence

In the early 1980s, the DuPont company, a chemical giant with deep roots in traditional industries, made a strategic decision to diversify into the higher-margin pharmaceutical business—a field in which it had little experience.[13] This corporate risk-taking set the stage for one of the decade's most important drug discoveries. The nascent pharmaceutical research program at DuPont was populated by a team of young scientists, including chemists David Carini and John Duncia, who had recently completed their PhDs and had minimal industrial research experience.[2]

The turning point in the search for an angiotensin II antagonist came not from a meticulously planned experiment but from a moment of serendipitous error.[13] Pharmacologist PC Wong, also new to industrial pharmacology, was tasked with evaluating compounds based on patents from Takeda Chemical Industries that described weakly active imidazole derivatives.[13] In a critical in vivo experiment, Wong accidentally administered a massive dose (100 mg/kg) of one of these compounds, S-8307, to a rat.[13] While the compound's binding affinity was known to be extremely weak, the results of this high-dose experiment unexpectedly demonstrated that the molecule was highly

selective in its action, blocking the effects of angiotensin II without affecting other pressor agents.[13] This accidental finding provided the crucial proof-of-concept: a nonpeptide molecule could indeed selectively antagonize the angiotensin II receptor. An experienced research manager, RI Taber, recognized the immense promise in this result and championed the pursuit of this new line of research, persuading others that this was a lead worth pursuing despite its low potency.[13]

This pivotal discovery initiated an intensive period of rational drug design led by chemists Carini and Duncia. Guided by computer modeling and chemical intuition, they systematically synthesized a series of structural variants of the Takeda lead compound.[13] Their goal was to meticulously modify the molecule to better mimic the binding portion of angiotensin II, thereby increasing its potency and optimizing its properties for oral absorption. This painstaking work, involving the addition of acidic functional groups and modifications to the imidazole core, culminated in March 1986 with the synthesis of DuP-753, the molecule that would become known as Losartan.[13] This new compound was a thousand times more potent than the original Takeda lead and possessed the desired oral activity, representing a monumental scientific breakthrough.[13]

2.3 From Discovery to Market: The DuPont-Merck Partnership and Regulatory Approval

Despite the scientific triumph, Losartan faced significant internal hurdles at DuPont. The company's marketing division, inexperienced in pharmaceuticals and daunted by the high costs of clinical development, viewed Losartan as a "me-too" drug in a crowded hypertension market and nearly decided to shelve the project or out-license it.[13] The research scientists and managers, however, understood the profound novelty of their discovery and advocated fiercely for its development.[13]

Ultimately, the path to market was secured through a strategic partnership. Recognizing their own lack of expertise in conducting large-scale, sophisticated clinical trials, DuPont approached Merck & Co., an established pharmaceutical leader.[13] Merck's leadership saw the immense potential in Losartan and agreed to a collaboration to co-develop and market the drug. This partnership was formalized in January 1990 and solidified with the creation of the DuPont Merck Pharmaceutical Company joint venture in 1991.[13] This collaboration provided the necessary clinical and regulatory expertise to navigate the complex path to approval.

The key regulatory milestones for Losartan followed this partnership. The molecule itself was patented in 1986, the year of its discovery.[4] A crucial patent covering its synthesis was filed by DuPont scientists in 1992.[14] Following successful clinical trials conducted under the joint venture, Losartan received its official approval from the U.S. Food and Drug Administration (FDA) on April 14, 1995.[12]

2.4 Commercial Profile and Legacy

Upon its launch, Losartan was marketed under the brand name Cozaar®.[4] A combination product containing Losartan and the diuretic hydrochlorothiazide was subsequently introduced as

Hyzaar®.[3] More recently, in March 2025, a ready-to-use oral suspension formulation was approved under the brand name

Arbli™ (10 mg/mL), providing a more convenient and safer dosing option for pediatric patients and adults with difficulty swallowing tablets.[19]

Losartan's patent protection eventually expired, and it has been available as a lower-cost generic medication since 2009.[14] This transition to generic status has made it widely accessible and affordable, solidifying its place as one of the most prescribed medications in the United States.[20] In recognition of its efficacy, safety, and importance in treating a major global health problem, Losartan is included on the World Health Organization's List of Essential Medicines.[4] Its discovery not only provided a vital new therapy but also served as the prototype for an entire class of drugs, the sartans, which have become indispensable in cardiovascular medicine.

Physicochemical Properties and Formulation

A thorough understanding of Losartan's physicochemical properties is essential for pharmacists, formulation scientists, and researchers, as these characteristics dictate its formulation, stability, storage, and behavior in biological systems. Losartan is typically administered as its potassium salt to enhance solubility and stability.

3.1 Chemical Identity and Structure

Losartan is a synthetic, nonpeptide molecule. Its formal chemical name is (2-butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazol-5-yl)methanol.[3] Structurally, it is classified as a biphenylyltetrazole, characterized by a 1,1'-biphenyl group that is substituted with a tetrazole ring at the 2'-position and an imidazol-1-ylmethyl group at the 4'-position.[12]

A key feature of its structure is the acidic tetrazole ring. This group was a critical innovation during its design, serving as a bioisostere—a chemical substitute with similar physical or chemical properties—for a carboxylic acid group.[4] This substitution was instrumental in achieving the high receptor affinity and pharmacological activity of the molecule. The overall structure includes a butyl group, a chloro substituent, and a hydroxymethyl group attached to the central imidazole ring, all of which contribute to its specific interaction with the AT1 receptor.

3.2 Physical and Chemical Properties

The properties of Losartan free base and its commonly used potassium salt differ, particularly in terms of solubility and melting point. The potassium salt is the form used in pharmaceutical preparations. The table below consolidates key physicochemical data from various sources.

Table 3.1: Physicochemical Properties of Losartan and Losartan Potassium

Property	Losartan (Base)	Losartan Potassium
CAS Number	114798-26-4 3	124750-99-8 23
Molecular Formula	C22​H23​ClN6​O 3	C22​H22​ClKN6​O 25
Molecular Weight	422.91 g/mol (Average) 3	461.01 g/mol 25
Appearance	Light yellow solid 12	White to off-white free-flowing crystalline powder 24
Melting Point	183–184 °C 21	263–265 °C 24
Solubility	Poorly soluble in water 12	Freely soluble in water and methanol; slightly soluble in acetonitrile 24
Stability	Stable under recommended storage conditions 12	Stable for 2 years as supplied; solutions in DMSO stable at -20°C for up to 2 months 24

3.3 Formulations and Excipients

Losartan is primarily available for oral administration. The most common formulations are solid tablets, which are marketed in strengths of 25 mg, 50 mg, and 100 mg of Losartan potassium.[27] These tablets contain a variety of inactive ingredients, or excipients, which are necessary for the manufacturing process and to ensure the stability and proper release of the active drug. Common excipients include microcrystalline cellulose (a binder and filler), lactose hydrous (a filler), pregelatinized starch (a disintegrant), and magnesium stearate (a lubricant).[26] The tablets are typically film-coated, with coatings that may contain hypromellose, hydroxypropyl cellulose, titanium dioxide, and carnauba wax.[26]

Recognizing the need for a more suitable formulation for pediatric patients and adults with dysphagia (difficulty swallowing), a ready-to-use oral liquid suspension was developed and approved.[19] This formulation, marketed as Arbli™, is available at a concentration of 10 mg/mL.[19] It offers a significant advantage over the practice of compounding tablets into a liquid, as it ensures accurate dosing, reduces the potential for contamination, and provides a stable, long-term shelf-life product.[19]

Clinical Pharmacology

The clinical effects of Losartan are a direct result of its specific interactions with the Renin-Angiotensin System (RAS) and its subsequent journey through the body. Its pharmacodynamic and pharmacokinetic profiles are well-characterized, revealing a sophisticated interplay between the parent drug and its highly active metabolite.

4.1 Pharmacodynamics (Mechanism of Action)

The pharmacodynamic effects of Losartan are centered on its ability to selectively and potently block the physiological actions of angiotensin II.

4.1.1 Primary Mechanism: AT1 Receptor Blockade

Losartan and its principal active metabolite, E-3174, function as selective antagonists of the Angiotensin II Type 1 (AT1) receptor.[4] They bind to this receptor with high affinity, competitively and reversibly preventing angiotensin II from binding and initiating its downstream signaling cascade.[3] This blockade occurs in critical tissues such as vascular smooth muscle and the adrenal glands.[3] The primary physiological actions of angiotensin II that are inhibited by this blockade are:

1. Potent Vasoconstriction: Angiotensin II is one of the body's most powerful vasoconstrictors. By blocking its action on the AT1 receptors of vascular smooth muscle, Losartan leads to relaxation of blood vessels.[6]
2. Aldosterone Secretion: Angiotensin II stimulates the adrenal cortex to release aldosterone, a hormone that promotes sodium and water retention by the kidneys.[4] By inhibiting this effect, Losartan promotes the excretion of sodium and water.[31]

The combined effect of these actions is a reduction in total peripheral resistance (afterload) and cardiac venous return (preload), which ultimately results in a decrease in systemic blood pressure.[4] The drug's selectivity is a key feature; it binds to the AT1 receptor with approximately 1,000 times more affinity than it does to the AT2 receptor.[3] The AT2 receptor is not known to be associated with cardiovascular homeostasis and may have counter-regulatory effects, so selective blockade of the AT1 receptor is considered the primary therapeutic mechanism.[33]

4.1.2 The Renin-Angiotensin System Feedback Loop

A predictable physiological consequence of blocking the AT1 receptor is the disruption of the system's natural negative feedback loop. The body's homeostatic mechanisms sense the reduced effect of angiotensin II and the drop in blood pressure. In response, the kidneys increase the secretion of renin.[4] This leads to a cascade that results in a compensatory 2- to 3-fold increase in plasma renin activity and, consequently, a rise in the circulating levels of angiotensin II.[4]

This compensatory rise in angiotensin II, however, does not overcome the therapeutic antihypertensive effect of Losartan. The reason for this lies in the nature of the receptor blockade. Although levels of the agonist (angiotensin II) increase, its target receptors (AT1) are already occupied by Losartan and, more importantly, by its highly potent, non-competitive metabolite, E-3174.[5] As a result, the elevated angiotensin II is unable to exert its pressor effects, and the blood pressure-lowering action of the drug is maintained. This phenomenon explains the sustained efficacy of Losartan despite the body's natural compensatory response.

4.1.3 Unique Uricosuric Effect

Beyond its primary effects on the RAS, Losartan possesses a clinically significant secondary mechanism: it is a uricosuric agent, meaning it promotes the excretion of uric acid in the urine.[4] This effect is not shared by all ARBs and distinguishes Losartan within its class. It achieves this by acting as a specific inhibitor of the urate transporter 1 (URAT1), also known as SLC22A12, which is located in the proximal tubules of the kidneys.[4] URAT1 is responsible for reabsorbing uric acid from the tubular fluid back into the bloodstream. By blocking this transporter, Losartan prevents this reabsorption, leaving more uric acid available to be filtered and excreted by the kidneys.[4] This mechanism can lead to a decrease in serum uric acid levels, which is particularly beneficial for patients with hypertension who also suffer from hyperuricemia or gout. In fact, the American College of Rheumatology has suggested Losartan as a preferred antihypertensive agent for this patient population.[10]

4.2 Pharmacokinetics (Absorption, Distribution, Metabolism, and Excretion)

The journey of Losartan through the body (ADME) is characterized by its conversion from a prodrug to a more potent active metabolite, which is central to its clinical utility.

4.2.1 Absorption and Distribution

Following oral administration, Losartan is well absorbed from the gastrointestinal tract. However, it undergoes substantial first-pass metabolism in the liver, which reduces its systemic bioavailability to approximately 33%.[4] Peak plasma concentrations (

Cmax​) of the parent drug, Losartan, are reached relatively quickly, at about 1 hour post-administration (Tmax​).[3] While taking the drug with food can slow the rate of absorption and decrease the peak concentration, it has a minimal effect on the total drug exposure, as measured by the area under the curve (AUC), for either Losartan or its active metabolite.[3]

Both Losartan and its active metabolite E-3174 are highly bound to plasma proteins, primarily albumin. The protein binding is greater than 98% for Losartan and approximately 99.7% for E-3174.[3] This high degree of protein binding results in a relatively small volume of distribution, measured at approximately 34 liters for Losartan and 12 liters for E-3174, indicating that the drug and its metabolite are largely confined to the vascular compartment.[3]

4.2.2 Metabolism: The Prodrug and its Active Metabolite

Losartan is a prodrug, meaning it is administered in an inactive or less active form and is then converted to its active form within the body. Approximately 14% of an oral dose of Losartan is metabolized into its principal active metabolite, E-3174, also known as losartan carboxylic acid.[3]

This critical biotransformation is an oxidation reaction that occurs primarily in the liver. It is catalyzed by enzymes of the cytochrome P450 system, specifically CYP2C9 and, to a lesser extent, CYP3A4.[4] The reaction proceeds through an intermediate aldehyde metabolite, designated EXP3179.[3]

The pharmacological significance of this metabolic conversion cannot be overstated. The E-3174 metabolite is substantially more potent than the parent drug, exhibiting 10 to 40 times the activity of Losartan at the AT1 receptor.[4] Furthermore, while Losartan is a competitive antagonist, E-3174 acts as a non-competitive, "insurmountable" antagonist, meaning its blockade is more robust and less easily overcome by increasing concentrations of angiotensin II.[11] This superior potency and insurmountable antagonism, combined with its longer half-life, means that E-3174 is responsible for the majority of the pharmacological effect observed after Losartan administration.

4.2.3 Table: Comparative Pharmacokinetics of Losartan and E-3174

The distinct pharmacokinetic profiles of Losartan and its active metabolite E-3174 are fundamental to understanding the drug's clinical action, particularly its suitability for once-daily dosing. The following table provides a direct comparison.

Table 4.1: Comparative Pharmacokinetics of Losartan and E-3174

Parameter	Losartan (Parent Drug)	E-3174 (Active Metabolite)
Time to Peak (Tmax​)	~1 hour 3	3–4 hours 3
Terminal Half-Life (t1/2​)	1.5–2.5 hours 3	6–9 hours 3
Relative Potency	1x	10–40x 4
Receptor Binding	Competitive 3	Non-competitive / Insurmountable 4
Plasma Protein Binding	~98.7% 3	~99.7% 3
Renal Clearance	~75 mL/min 3	~25 mL/min 3

4.2.4 Elimination

Losartan and its metabolites are eliminated from the body through both renal and biliary pathways. Following an oral dose of radiolabeled Losartan, approximately 35% of the radioactivity is recovered in the urine, while the remaining 60% is recovered in the feces, reflecting significant biliary excretion.[3] A very small fraction of the dose is excreted as unchanged drug in the urine (about 4%), with about 6% being excreted as the active metabolite E-3174.[3] The total plasma clearance of Losartan is approximately 600 mL/min, whereas the clearance of the more slowly eliminated E-3174 is about 50 mL/min.[3]

4.3 Pharmacogenomics

The metabolism of Losartan to its active form is significantly influenced by an individual's genetic makeup, a field known as pharmacogenomics. The primary enzyme responsible for this conversion, CYP2C9, is known to be highly polymorphic, meaning numerous genetic variants (alleles) exist in the population that can alter the enzyme's function.[35]

The most well-studied variant alleles, such as CYP2C9*2 and CYP2C9*3, are associated with decreased enzymatic activity.[35] Clinical studies have demonstrated that individuals who carry one or more copies of the

CYP2C9*3 allele exhibit a significantly reduced capacity to metabolize Losartan into its active metabolite, E-3174.[36] In these "poor metabolizers," the plasma and urine concentrations of E-3174 are substantially lower, and the ratio of the parent drug to the active metabolite is markedly higher compared to individuals with the normal (wild-type) enzyme.[37]

This genetic variability has direct clinical implications. Since the majority of Losartan's therapeutic effect is derived from the potent E-3174 metabolite, a patient with a genotype that leads to impaired CYP2C9 function will produce less of this active compound. This can result in a diminished antihypertensive response to a standard dose of the medication. Consequently, such patients may require higher doses of Losartan to achieve blood pressure control, or they may benefit from being treated with an alternative ARB that does not rely on CYP2C9 for its activation or clearance. This link between a patient's genetic profile and their response to Losartan highlights the growing importance of personalized medicine in cardiovascular therapy.

Clinical Applications and Efficacy

Losartan is a widely prescribed medication with well-established efficacy in several key cardiovascular and renal conditions. Its use is supported by extensive clinical trial data and is reflected in its FDA-approved indications and common off-label applications.

5.1 FDA-Approved Indications

The U.S. Food and Drug Administration has approved Losartan for three primary indications:

5.1.1 Hypertension

Losartan is indicated for the management of hypertension, either as a monotherapy or in combination with other classes of antihypertensive agents.[8] It is approved for use in adults and in pediatric patients aged 6 years and older.[3] Major evidence-based clinical guidelines recognize ARBs like Losartan as one of several preferred agents for the initial management of hypertension, placing it on par with ACE inhibitors, thiazide diuretics, and calcium channel blockers.[8]

5.1.2 Stroke Risk Reduction in Patients with LVH

In patients who have both hypertension and evidence of left ventricular hypertrophy (LVH)—a thickening of the heart's main pumping chamber—Losartan is indicated to reduce the risk of stroke.[3] This indication is based on the landmark Losartan Intervention For Endpoint reduction in hypertension (LIFE) study, which demonstrated a significant reduction in the primary composite endpoint of cardiovascular death, stroke, and myocardial infarction compared to the beta-blocker atenolol.[38] However, it is critically important to note that a sub-analysis of the trial data revealed that this benefit does not appear to extend to Black patients.[3] This finding underscores the need for careful consideration of patient race in therapy selection for this specific indication.

5.1.3 Diabetic Nephropathy

Losartan is indicated for the treatment of diabetic nephropathy in patients with type 2 diabetes mellitus and a history of hypertension.[3] The specific patient population for this indication includes those with evidence of renal damage, manifested by elevated serum creatinine and proteinuria (defined as a urinary albumin-to-creatinine ratio of ≥300 mg/g).[8] The goal of therapy is to delay the progression of renal disease. This indication is supported by the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial, which showed that Losartan significantly reduced the risk of doubling of serum creatinine, progression to end-stage renal disease, or death.[38]

5.2 Off-Label and Investigational Uses

Beyond its approved indications, clinicians use Losartan for other conditions based on its mechanism of action and emerging evidence.

• Heart Failure: Losartan is commonly used off-label in the management of chronic heart failure with reduced ejection fraction (HFrEF).[4] According to major cardiology guidelines, it serves as an essential alternative for patients who are intolerant to first-line therapies, such as ACE inhibitors (often due to cough) or Angiotensin Receptor-Neprilysin Inhibitors (ARNIs) like sacubitril/valsartan.[7]
• Other Uses: Losartan has been used off-label in the management of Marfan syndrome, an inherited connective tissue disorder, to potentially slow the rate of aortic root dilation.[10] It has also been subject to investigational research for other conditions. For example, a completed Phase 4 clinical trial explored its effects on periodic breathing during sleep in hypoxic conditions, suggesting ongoing research into its broader physiological effects.[39]

5.3 Clinical Efficacy and Onset of Action

While Losartan begins working with the first dose, its full therapeutic effect is not immediate. Patients may notice an initial drop in blood pressure within the first week of treatment.[7] However, the maximal antihypertensive effects are typically observed after 3 to 6 weeks of continuous therapy.[4] This delayed onset of maximal effect is an important point for patient counseling, as it helps manage expectations and encourages adherence during the initial weeks of treatment before the full benefit is realized.

Dosing, Administration, and Monitoring

The safe and effective use of Losartan requires appropriate dosing based on the specific indication and patient characteristics, along with diligent monitoring of key clinical and laboratory parameters.

6.1 Dosing and Administration

Losartan is administered orally, typically once daily. The dosage must be individualized based on the clinical indication and the patient's response to therapy. The following table summarizes the recommended dosing regimens.

Table 6.1: Recommended Dosing Regimens for Losartan by Indication

Indication	Patient Population	Starting Dose	Titration / Target Dose	Maximum Daily Dose
Hypertension	Adults	50 mg once daily 10	May be increased based on blood pressure response 10	100 mg once daily 10
Hypertension	Pediatric (≥6 years)	0.7 mg/kg once daily (up to 50 mg) 5	May be increased up to 1.4 mg/kg based on response 5	1.4 mg/kg or 100 mg (whichever is lower) 5
Stroke Risk Reduction (with LVH)	Adults	50 mg once daily 32	May add hydrochlorothiazide and/or increase Losartan to 100 mg daily based on response 38	100 mg once daily 38
Diabetic Nephropathy	Adults	50 mg once daily 10	May be increased to 100 mg daily based on blood pressure response 10	100 mg once daily 10
Heart Failure (HFrEF, Off-label)	Adults	25–50 mg once daily 10	Titrate upwards as tolerated towards target dose 38	150 mg once daily 10

Losartan can be taken with or without food.[10] While it can be administered at any time of day, taking it at approximately the same time each day is recommended to maintain consistent plasma levels and improve adherence.[10] For the first dose, some clinicians may advise taking it at bedtime to mitigate potential initial dizziness.[27]

6.2 Special Populations and Dose Adjustments

Dosage adjustments are necessary for certain patient populations to ensure safety and efficacy.

• Hepatic Impairment: Patients with a history of mild-to-moderate hepatic impairment exhibit approximately two-fold higher oral bioavailability and five-fold higher plasma concentrations of Losartan compared to healthy individuals.[8] Therefore, a lower starting dose of 25 mg once daily is recommended for this population.[10] Losartan has not been studied in patients with severe hepatic impairment and should be used with caution.[5]
• Renal Impairment: In general, no initial dosage adjustment is required for patients with mild-to-moderate renal insufficiency.[10] However, if the patient is also volume-depleted, a lower starting dose is prudent. For patients with severe renal impairment (e.g., GFR < 20 mL/min), an initial dose of 25 mg daily is advised.[5] It is important to note that neither Losartan nor its active metabolite is removed by hemodialysis, so no supplemental dose is needed after dialysis.[5]
• Volume Depletion: Patients who may be intravascularly volume-depleted, such as those receiving high doses of diuretics, are at an increased risk of symptomatic hypotension upon initiation of Losartan. For these patients, a lower starting dose of 25 mg once daily is recommended.[8]
• Geriatric Patients: For patients over the age of 75, a lower starting dose of 25 mg daily may be considered, particularly when used for the indication of renal protection.[27]

6.3 Patient Monitoring

To ensure the safe use of Losartan, regular monitoring of specific parameters is essential.

1. Blood Pressure: Routine monitoring of blood pressure is fundamental to assess the drug's efficacy and to guide dose titration to achieve target goals.[8]
2. Serum Potassium: Periodic measurement of serum potassium is crucial due to the risk of hyperkalemia.[3] This is especially important in patients with renal impairment, diabetes, heart failure, or those taking concomitant medications that can also increase potassium levels (e.g., potassium-sparing diuretics, potassium supplements).[10]
3. Renal Function: Periodic assessment of renal function, typically by measuring serum creatinine and calculating the estimated glomerular filtration rate (eGFR), is necessary.[3] ARBs can affect renal hemodynamics, and monitoring is required to detect any significant decline in kidney function.[10]

Safety, Tolerability, and Risk Management

Losartan is generally well-tolerated, but like all medications, it carries risks of adverse effects and requires careful management to ensure patient safety. Its safety profile is defined by a prominent black box warning, specific contraindications, and a spectrum of potential adverse reactions and drug interactions.

7.1 Black Box Warning: Fetal Toxicity

Losartan carries a U.S. FDA Black Box Warning, the most serious type of warning, regarding its use during pregnancy.[8]

• Warning: Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. When pregnancy is detected, Losartan should be discontinued as soon as possible.[8]
• Mechanism of Harm: Use of Losartan during the second and third trimesters of pregnancy can lead to fetal and neonatal morbidity and mortality. The mechanism is believed to be related to the drug's effects on fetal renal function and blood pressure regulation. This can result in oligohydramnios (deficient amniotic fluid), which is associated with severe complications including fetal lung hypoplasia, skeletal deformities (e.g., calvarial hypoplasia), and neonatal anuria, hypotension, and renal failure.[8]
• Clinical Directive: Due to this significant risk, Losartan is contraindicated in pregnancy. Females of reproductive potential should be counseled on the risks, and pregnancy status should be verified before initiating therapy. If a patient becomes pregnant while taking Losartan, the medication must be stopped immediately, and the patient should be apprised of the potential hazards to the fetus.[8]

7.2 Contraindications and Precautions

In addition to pregnancy, there are other situations where Losartan use is contraindicated or requires significant caution.

• Contraindications:
• Hypersensitivity: Losartan is contraindicated in patients with a known hypersensitivity to the drug or any of its components.[5]
• Concomitant Aliskiren Use: The co-administration of Losartan with the direct renin inhibitor aliskiren is contraindicated in patients with diabetes mellitus due to an increased risk of renal impairment, hyperkalemia, and hypotension.[8]
• Precautions:
• Renal Artery Stenosis: Use with caution in patients with unilateral or bilateral renal artery stenosis, as drugs affecting the RAS can exacerbate renal dysfunction.[5]
• Angioedema: Patients with a prior history of angioedema (swelling of the face, lips, tongue, or throat), particularly if related to ACE inhibitor therapy, may be at an increased risk and should be monitored closely.[10]
• Hypotension: In patients who are volume- or salt-depleted (e.g., from diuretic therapy, diarrhea, or vomiting), Losartan can cause symptomatic hypotension. Correction of this depletion or use of a lower starting dose is recommended.[5]

7.3 Adverse Effects

The adverse effect profile of Losartan ranges from common, mild effects to rare but serious, life-threatening reactions.

Table 7.1: Common and Serious Adverse Effects of Losartan

Frequency	System / Effect	Key Symptoms and Management
Common (>1%)	Dizziness / Hypotension	Feeling lightheaded, especially upon standing. Advise slow position changes. May require dose reduction if persistent.4
	Upper Respiratory Infection	Symptoms of the common cold, stuffy nose, or sinus infection. Generally mild.42
	Fatigue / Asthenia	Feeling tired or weak. Often transient.5
	Musculoskeletal Pain	Back pain or muscle cramps.4
	Gastrointestinal Effects	Diarrhea, dyspepsia. Taking with food may help.5
	Hyperkalemia (Mild)	Mildly elevated potassium levels. Requires monitoring but may not be clinically significant in all patients.4
	Cough	A dry, persistent cough can occur, but the incidence is significantly lower than with ACE inhibitors and similar to placebo.3
Serious / Rare (<1%)	Angioedema	Swelling of the face, lips, tongue, or throat, which can compromise the airway. Medical emergency. Discontinue immediately and do not re-challenge.4
	Severe Hypotension	Fainting, severe dizziness, confusion. Requires immediate medical attention.31
	Acute Renal Failure	Decreased urine output, swelling in legs/ankles, fatigue. Requires discontinuation and medical management.5
	Severe Hyperkalemia	Muscle weakness, slow or irregular heartbeat, breathing difficulty. Can be life-threatening. Medical emergency.31
	Hepatitis	Yellowing of skin or eyes (jaundice), severe stomach pain. Requires discontinuation and medical evaluation.5
	Rhabdomyolysis	Severe, unexplained muscle pain and weakness, dark urine. Can lead to kidney failure. Requires immediate medical attention.5
	Anaphylaxis	Severe, whole-body allergic reaction with hives, difficulty breathing, and swelling. Medical emergency.5

7.4 Drug and Food Interactions

Losartan can interact with other medications, supplements, and certain foods, potentially altering its efficacy or increasing the risk of adverse effects.

Table 7.2: Clinically Significant Drug and Food Interactions with Losartan

Interacting Agent	Mechanism of Interaction	Clinical Consequence	Management Recommendation
Potassium-Sparing Diuretics (e.g., Spironolactone), Potassium Supplements, Salt Substitutes containing Potassium	Additive potassium-retaining effects.4	Increased risk of developing severe hyperkalemia.	Avoid concomitant use when possible. If necessary, monitor serum potassium levels very closely.10
Nonsteroidal Anti-inflammatory Drugs (NSAIDs) (e.g., Ibuprofen, Naproxen, Celecoxib)	Inhibition of renal prostaglandin synthesis, which can reduce renal blood flow and promote sodium retention.10	Can reduce the antihypertensive effect of Losartan. Increased risk of acute kidney injury, especially in elderly, volume-depleted, or renally impaired patients.	Avoid chronic concomitant use if possible. If necessary, monitor blood pressure and renal function periodically.10
Lithium	Losartan can reduce the renal clearance of lithium.5	Increased serum lithium concentrations and a higher risk of lithium toxicity.	Monitor serum lithium levels frequently if co-administration is unavoidable. A reduction in lithium dosage may be required.10
Dual RAS Blockade (ACE Inhibitors, other ARBs, Aliskiren)	Synergistic blockade of the Renin-Angiotensin System.10	Increased risk of hypotension, hyperkalemia, and acute renal failure compared to monotherapy, without providing additional benefit.	Combination is generally not recommended. Co-administration with aliskiren is contraindicated in patients with diabetes.8
Grapefruit and Grapefruit Juice	Potential inhibition of intestinal cytochrome P450 enzymes involved in drug metabolism.44	May decrease the efficacy of Losartan by interfering with its absorption or metabolism.	Patients may be advised to avoid consuming grapefruit products while taking Losartan.45
Alcohol	Additive vasodilatory and blood pressure-lowering effects.31	Increased risk of dizziness, lightheadedness, and orthostatic hypotension.	Counsel patients to use caution when consuming alcohol. Advise them to avoid driving or hazardous activities until they know how the combination affects them.47

Comparative Analysis and Future Perspectives

As the first-in-class ARB, Losartan set the standard against which subsequent agents have been measured. Its position in the therapeutic armamentarium is best understood through comparison with other members of its class and by examining its broader biological effects beyond simple receptor blockade.

8.1 Losartan within the ARB Class: A Comparison with Valsartan and Olmesartan

While all ARBs share the same fundamental mechanism of AT1 receptor blockade, they exhibit important differences in their pharmacokinetic profiles, potency, and evidence base for specific clinical indications. The choice among them is often a nuanced decision based on individual patient factors. A comparison with two other prominent ARBs, Valsartan and Olmesartan, illuminates these distinctions.

The selection of an ARB is not merely a question of which agent is most potent, but rather a sophisticated clinical decision that balances efficacy, metabolic predictability, unique ancillary benefits, and the strength of evidence for specific patient populations. For instance, some meta-analyses suggest that Olmesartan may provide a greater reduction in blood pressure compared to Losartan and Valsartan at standard starting doses.[48] However, this higher potency must be weighed against other factors.

Losartan's efficacy is intrinsically linked to its metabolism by the polymorphic CYP2C9 enzyme. This makes its therapeutic effect potentially less predictable in individuals with certain genetic variants or those taking drugs that inhibit or induce this enzyme. In contrast, Valsartan undergoes only minimal metabolism (primarily by CYP2C9 to an inactive metabolite), and Olmesartan is not metabolized by the cytochrome P450 system at all (it is a prodrug hydrolyzed to its active form during absorption).[33] This gives Valsartan and Olmesartan more predictable pharmacokinetic profiles with a lower potential for certain types of drug-drug interactions.

Conversely, each agent has unique attributes. Losartan's uricosuric effect makes it a compelling choice for hypertensive patients with gout.[4] Valsartan has a specific FDA approval for use in patients post-myocardial infarction and is the ARB component of the leading Angiotensin Receptor-Neprilysin Inhibitor (ARNI), sacubitril/valsartan (Entresto), giving it a strong evidence base in heart failure.[52] Olmesartan, while potent, carries a rare but specific warning for sprue-like enteropathy, a severe form of diarrhea and weight loss.[52] Therefore, the optimal choice of ARB is not universal but must be tailored to the individual patient's complete clinical picture, including comorbidities, concomitant medications, and therapeutic goals.

Table 8.1: Comparative Profile of Losartan, Valsartan, and Olmesartan

Feature	Losartan	Valsartan	Olmesartan
Metabolism	Prodrug; extensive metabolism by CYP2C9/3A4 to a highly potent active metabolite (E-3174).35	Minimal metabolism, primarily by CYP2C9 to a largely inactive metabolite.33	Prodrug; hydrolyzed to active form during absorption. No significant CYP450 metabolism.50
Blood Pressure Lowering Efficacy	Effective, serves as a benchmark.	Generally considered similar in efficacy to Losartan.52	Meta-analyses suggest potentially greater blood pressure reduction than Losartan or Valsartan.48
Half-life (Active form)	6–9 hours (for E-3174) 3	~6 hours 33	10–15 hours 51
Unique Features	Prominent uricosuric effect (beneficial in gout).4	FDA-approved for post-myocardial infarction management; ARB component of Entresto.52	High potency; associated with a rare risk of sprue-like enteropathy.52
Key FDA Indications	Hypertension, Diabetic Nephropathy, Stroke Risk Reduction (with LVH).8	Hypertension, Heart Failure, Post-Myocardial Infarction.53	Hypertension.50

8.2 Pleiotropic Effects and Future Research Directions

Emerging research suggests that the benefits of Losartan may extend beyond simple AT1 receptor blockade. These additional, or "pleiotropic," effects could help explain some of the positive outcomes observed in large clinical trials that were not fully attributable to blood pressure reduction alone.

A particularly intriguing finding relates to one of Losartan's intermediate metabolites, EXP3179 (the aldehyde precursor to the active E-3174 metabolite). Studies have shown that EXP3179, while having no AT1-blocking properties itself, acts as a partial agonist of the Peroxisome Proliferator-Activated Receptor gamma (PPARγ).[54] This is highly significant because PPARγ is a nuclear receptor that plays a key role in regulating glucose metabolism and inflammation. It is the molecular target for the thiazolidinedione class of anti-diabetic drugs (e.g., pioglitazone).

The activation of PPARγ is associated with increased insulin sensitivity and anti-inflammatory effects. This finding provides a potential molecular mechanism to explain the observation from large trials like LIFE and VALUE, where ARB therapy was associated with a lower incidence of new-onset diabetes compared to other antihypertensive classes.[54] This suggests that Losartan therapy may confer a dual benefit in at-risk patients: AT1 receptor blockade from Losartan and its E-3174 metabolite, and a simultaneous, beneficial metabolic effect from the PPARγ activity of its EXP3179 metabolite. This area represents a promising direction for future research to further elucidate the full spectrum of Losartan's biological actions and its potential role in preventing metabolic disease.

8.3 Concluding Remarks

Losartan holds a distinguished place in the history of pharmacotherapy. As the pioneering Angiotensin II Receptor Blocker, it provided a vital and better-tolerated alternative to ACE inhibitors, fundamentally reshaping the approach to managing hypertension and related cardiovascular diseases. Its development from a serendipitous discovery to a blockbuster drug is a testament to the power of scientific persistence and strategic collaboration.

Over decades of clinical use, Losartan has demonstrated robust efficacy and a well-characterized safety profile. Its unique combination of AT1 receptor blockade and a secondary uricosuric effect provides distinct advantages in specific patient populations. While newer agents have since joined the ARB class, each with its own set of properties, Losartan's long history of use, extensive clinical data, and affordability as a generic medication ensure its continued and essential role in medicine. The ongoing exploration of its pleiotropic effects suggests that even after more than 25 years on the market, the full story of this archetypal molecule may still be unfolding. It remains a cornerstone of cardiovascular therapy, preventing morbidity and mortality for millions of patients worldwide.

Works cited

1. Discovery of losartan, the first angiotensin II receptor antagonist - PubMed, accessed July 17, 2025, https://pubmed.ncbi.nlm.nih.gov/8583479/
2. How the antihypertensive losartan was discovered - ResearchGate, accessed July 17, 2025, https://www.researchgate.net/publication/236058547_How_the_antihypertensive_losartan_was_discovered
3. Losartan: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed July 17, 2025, https://go.drugbank.com/drugs/DB00678
4. Losartan - Wikipedia, accessed July 17, 2025, https://en.wikipedia.org/wiki/Losartan
5. Losartan - Mechanism, Indication, Contraindications, Dosing, Adverse Effect, Interaction, Renal Dose, Hepatic Dose | Drug Index | Pediatric Oncall, accessed July 17, 2025, https://www.pediatriconcall.com/drugs/losartan/723
6. www.mayoclinic.org, accessed July 17, 2025, https://www.mayoclinic.org/drugs-supplements/losartan-oral-route/description/drg-20067341#:~:text=Losartan%20is%20an%20angiotensin%20II,and%20oxygen%20to%20the%20heart.
7. How Does Losartan Work? Its Mechanism of Action Explained - GoodRx, accessed July 17, 2025, https://www.goodrx.com/losartan/mechanism-of-action
8. Losartan Potassium Monograph for Professionals - Drugs.com, accessed July 17, 2025, https://www.drugs.com/monograph/losartan-potassium.html
9. These highlights do not include all the information needed to use LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE TABLETS safely and effectively. See full prescribing information for LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE TABLETS. LOSARTAN POTASSIUM and HYDROCHLOROTHIAZIDE tablets, USP for oral use Initial U.S. Approval: 1995 - DailyMed, accessed July 17, 2025, https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=a04b5622-2c49-4d61-92b1-5dc523af7a24&type=display
10. Losartan - StatPearls - NCBI Bookshelf, accessed July 17, 2025, https://www.ncbi.nlm.nih.gov/books/NBK526065/
11. Clinical pharmacokinetics of losartan - PubMed, accessed July 17, 2025, https://pubmed.ncbi.nlm.nih.gov/16029066/
12. Losartan | C22H23ClN6O | CID 3961 - PubChem, accessed July 17, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Losartan
13. How the antihypertensive losartan was discovered, accessed July 17, 2025, https://www.tandfonline.com/doi/pdf/10.1517/17460441.1.6.609
14. Losartan - American Chemical Society, accessed July 17, 2025, https://www.acs.org/molecule-of-the-week/archive/l/losartan.html
15. Losartan: a medicine to treat high blood pressure - NHS, accessed July 17, 2025, https://www.nhs.uk/medicines/losartan/
16. www.goodrx.com, accessed July 17, 2025, https://www.goodrx.com/losartan/what-is#:~:text=Losartan%2C%20also%20known%20by%20the,in%20certain%20people%20with%20diabetes.
17. Losartan | CAS 114798-26-4 | SCBT - Santa Cruz Biotechnology, accessed July 17, 2025, https://www.scbt.com/p/losartan-114798-26-4
18. Losartan - brand name list from Drugs.com, accessed July 17, 2025, https://www.drugs.com/ingredient/losartan.html
19. FDA Approves Losartan Potassium for Reduction in Risk of Stroke - Drug Topics, accessed July 17, 2025, https://www.drugtopics.com/view/fda-approves-losartan-potassium-for-reduction-in-risk-of-stroke
20. Cozaar (Losartan) Dosages for Adults and Children - GoodRx, accessed July 17, 2025, https://www.goodrx.com/losartan/losartan-dosage
21. Losartan - CAS Common Chemistry, accessed July 17, 2025, https://commonchemistry.cas.org/detail?cas_rn=114798-26-4&search=114798-26-4
22. Losartan | 114798-26-4 - ChemicalBook, accessed July 17, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB8120081.htm
23. CAS 114798-26-4 Losartan - BOC Sciences, accessed July 17, 2025, https://www.bocsci.com/product/losartan-cas-114798-26-4-54987.html
24. Losartan potassium | 124750-99-8 - ChemicalBook, accessed July 17, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB1442564.htm
25. en.wikipedia.org, accessed July 17, 2025, https://en.wikipedia.org/wiki/Losartan#:~:text=9%20External%20links-,Chemistry,its%20molecular%20weight%20is%20422.9.
26. COZAAR® (LOSARTAN POTASSIUM TABLETS) Page 1 of 28 - accessdata.fda.gov, accessed July 17, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020386s058lbl.pdf
27. How and when to take losartan - NHS, accessed July 17, 2025, https://www.nhs.uk/medicines/losartan/how-and-when-to-take-losartan/
28. Losartan tablet dosage: Strengths, when to use, and more - Medical News Today, accessed July 17, 2025, https://www.medicalnewstoday.com/articles/drugs-losartan-tablet-dosage
29. Losartan (Cozaar): Uses, Side Effects, Dosage & More - GoodRx, accessed July 17, 2025, https://www.goodrx.com/losartan/what-is
30. Losartan Potassium Tablets, accessed July 17, 2025, https://pdf.hres.ca/dpd_pm/00049364.PDF
31. Losartan (Cozaar, Arbli): Uses, Side Effects, Interactions, Pictures, Warnings & Dosing, accessed July 17, 2025, https://www.webmd.com/drugs/2/drug-6616/losartan-oral/details
32. Losartan (oral route) - Side effects & dosage - Mayo Clinic, accessed July 17, 2025, https://www.mayoclinic.org/drugs-supplements/losartan-oral-route/description/drg-20067341
33. Diovan® - accessdata.fda.gov, accessed July 17, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021283s018lbl.pdf
34. Valsartan: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed July 17, 2025, https://go.drugbank.com/drugs/DB00177
35. Mathematical modeling of pharmacokinetics and pharmacodynamics of losartan in relation to CYP2C9 allele variants - Frontiers, accessed July 17, 2025, https://www.frontiersin.org/journals/systems-biology/articles/10.3389/fsysb.2025.1504077/full
36. Losartan Pathway, Pharmacokinetics - PharmGKB, accessed July 17, 2025, https://www.pharmgkb.org/pathway/PA164713428
37. (PDF) Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype - ResearchGate, accessed July 17, 2025, https://www.researchgate.net/publication/11536040_Pharmacokinetics_of_losartan_and_its_metabolite_E-3174_in_relation_to_the_CYP2C9_genotype
38. Losartan: uses, dosing, warnings, adverse events, interactions - MedCentral, accessed July 17, 2025, https://www.medcentral.com/drugs/monograph/6616-395008/losartan-oral
39. Oxygen Deficiency Completed Phase 4 Trials for Losartan (DB00678) | DrugBank Online, accessed July 17, 2025, https://go.drugbank.com/indications/DBCOND0081250/clinical_trials/DB00678?phase=4&status=completed
40. The pharmacokinetics of losartan in renal insufficiency | Health & Environmental Research Online (HERO) | US EPA, accessed July 17, 2025, https://hero.epa.gov/hero/index.cfm/reference/details/reference_id/6951028
41. Side effects of losartan - NHS, accessed July 17, 2025, https://www.nhs.uk/medicines/losartan/side-effects-of-losartan/
42. Losartan potassium: Side effects, dosage, uses, and more - Medical News Today, accessed July 17, 2025, https://www.medicalnewstoday.com/articles/losartan-oral-tablet
43. 13 Losartan Side Effects You Should Know About - GoodRx, accessed July 17, 2025, https://www.goodrx.com/losartan/common-side-effects
44. Losartan – Health Information Library - PeaceHealth, accessed July 17, 2025, https://www.peacehealth.org/medical-topics/id/hn-1428003
45. Losartan and interactions: Other drugs, alcohol, and more - Medical News Today, accessed July 17, 2025, https://www.medicalnewstoday.com/articles/drugs-losartan-tablet-interactions
46. www.drugs.com, accessed July 17, 2025, https://www.drugs.com/food-interactions/losartan.html#:~:text=In%20some%20patients%20grapefruits%20and,is%20not%20expected%20to%20interact.
47. Hydrochlorothiazide/losartan and Alcohol/Food Interactions - Drugs.com, accessed July 17, 2025, https://www.drugs.com/food-interactions/hydrochlorothiazide-losartan.html
48. Antihypertensive effects of olmesartan compared with other ... - NCBI, accessed July 17, 2025, https://www.ncbi.nlm.nih.gov/books/NBK114431/
49. Identification of cytochrome P450 forms involved in the 4-hydroxylation of valsartan, a potent and specific angiotensin II receptor antagonist, in human liver microsomes - PubMed, accessed July 17, 2025, https://pubmed.ncbi.nlm.nih.gov/16192110/
50. Clinical and experimental aspects of olmesartan medoxomil, a new angiotensin II receptor antagonist - PubMed, accessed July 17, 2025, https://pubmed.ncbi.nlm.nih.gov/15592575/
51. Product Information for Olmetec (olmesartan medoxomil) - Therapeutic Goods Administration (TGA), accessed July 17, 2025, https://www.tga.gov.au/sites/default/files/auspar-olmesartan-medoxomil-130226-pi.pdf
52. Which ARB Medication Should You Take? Comparing Losartan, Olmesartan, Telmisartan, and Valsartan - GoodRx, accessed July 17, 2025, https://www.goodrx.com/classes/arbs/losartan-vs-olmesartan-vs-telmisartan-which-is-best
53. Valsartan - Wikipedia, accessed July 17, 2025, https://en.wikipedia.org/wiki/Valsartan
54. Chronic Treatment With Losartan Results in Sufficient Serum Levels of the Metabolite EXP3179 for PPARγ Activation | Hypertension - American Heart Association Journals, accessed July 17, 2025, https://www.ahajournals.org/doi/10.1161/hypertensionaha.109.132886